Rapid Changes in Laboratory Parameters and Early Response to Adalimumab: A Pooled Analysis From Patients With Ulcerative Colitis in Two Clinical Trials

BACKGROUND AND AIMS: The efficacy and safety of adalimumab for induction and maintenance of clinical remission in patients with moderately to severely active ulcerative colitis were demonstrated in the ULTRA 1 and 2 clinical trials. This post-hoc, pooled analysis evaluated early changes in laborator...

Descripción completa

Detalles Bibliográficos
Autores principales: Hanauer, Stephen, Sandborn, William J, Colombel, Jean-Frederic, Vermeire, Severine, Petersson, Joel, Kligys, Kristina, Zhou, Qian, Lazar, Andreas, Reinisch, Walter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6751337/
https://www.ncbi.nlm.nih.gov/pubmed/30726897
http://dx.doi.org/10.1093/ecco-jcc/jjz031

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6751337/
https://www.ncbi.nlm.nih.gov/pubmed/30726897
http://dx.doi.org/10.1093/ecco-jcc/jjz031

Ejemplares similares